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Prion diseases are neurodegenerative diseases characterized
by the conversion of the cellular prion protein PrPc into a
pathogenic isoform PrPsc. Passive immunization with anti-
prion monoclonal antibodies can arrest the progression of
prion diseases. Here, the crystal structure of the Fab fragment
of an antiprion monoclonal antibody, POM1, in complex with
human prion protein (huPrPc) has been determined to 2.4 Å
resolution. The prion epitope of POM1 is in close proximity to
the epitope recognized by the purportedly therapeutic anti-
body fragment ICSM18 Fab in complex with huPrPc. POM1
Fab forms a 1:1 complex with huPrPc and the measured Kd
of 4.5  107 M reveals moderately strong binding between
them. Structural comparisons have been made among three
prion–antibody complexes: POM1 Fab–huPrPc, ICSM18 Fab–
huPrPc and VRQ14 Fab–ovPrPc. The prion epitopes recog-
nized by ICSM18 Fab and VRQ14 Fab are adjacent to a prion
glycosylation site, indicating possible steric hindrance and/or
an altered binding mode to the glycosylated prion protein
in vivo. However, both of the glycosylation sites on huPrPc are
positioned away from the POM1 Fab binding epitope; thus,
the binding mode observed in this crystal structure and the
binding affinity measured for this antibody are most likely to
be the same as those for the native prion protein in vivo.
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1. Introduction
Prion diseases affect a variety of mammalian species and are
collectively known as transmissible spongiform encephal-
opathies (TSEs); they include bovine spongiform encephal-
opathy (BSE) in cattle, chronic wasting disease (CWD) in
cervids, scrapie in sheep and goats and Creutzfeldt–Jakob
disease (CJD) in humans (Aguzzi & Polymenidou, 2004).
These are progressively degenerative disorders of the central
nervous system that result in motor dysfunction, dementia and
ultimately death (Collinge, 2001). Different fatal forms of
human prion diseases are also known; these are kuru, variant
Creutzfeldt–Jakob disease (vCJD), Gerstmann–Straussler–
Scheinker syndrome (GSS) and fatal familial insomnia (FFI)
(Collinge, 2001). The hallmark of prion diseases is the accu-
mulation of amyloid fibrils in the brain tissue, resulting in
excessive neuronal degeneration and spongiosis (Will, 1999).
The conversion of normal cellular prion protein (PrPc), which
is ubiquitously expressed in the human body and is especially
abundant in brain tissue, into a pathogenic conformation
(PrPsc) is the crucial step in the onset of this disease. This
pathogenic prion conformation, PrPsc, possesses abnormal
physicochemical properties such as resistance to proteolytic
degradation, insolubility and a propensity to polymerize
into amyloid-like fibrils. According to the ‘protein-only’
hypothesis, transmission of TSEs is completely a PrPsc-
dependent phenomenon; PrPsc acts as a template for its self-
propagation as well as for its replication through recruiting
normal cellular prion molecules and the cycle continues,
leading to the formation of amyloid fibrils (Sigurdson et al.,
2009; Castilla et al., 2005). During this PrPsc conversion
process the helical nature of the cellular prion protein is
almost completely lost, giving rise to -strands and turns,
which then aggregate amongst themselves, forming long
extended fibril-like structures (Smirnovas et al., 2011).
Until now there has been no treatment available either to
cure or to halt the progression of prion diseases; however, any
interruption in the pathogenic conversion process of PrPc
to PrPsc at the neuronal level could potentially prevent the
progression of these diseases (White et al., 2003). One of the
therapeutic approaches considered for the treatment of prion
diseases has been the use of antiprion monoclonal antibodies
as a passive immunization agent that could possibly reduce
PrPsc accumulation by disrupting the vicious pathological
cycle of PrPc-to-PrPsc conversion (White et al., 2003;
Antonyuk et al., 2009). The proposed mechanism by which
these antibodies may reduce levels of PrPsc is that antiprion
monoclonal antibodies bind to the PrPc molecule and stabilize
it in its native conformation through tight binding, thus
preventing any untoward conformational changes. A different
conformation of the prion molecule, known as PrP, has been
implicated in initiation of PrPsc formation and prion propa-
gation (Hosszu et al., 2009). Several in vitro and in vivo studies
of antiprion monoclonal antibodies have been reported to
reduce the amount of scrapie prion (White et al., 2003;
Féraudet et al., 2005). Furthermore, an in vivo study in a
murine model also suggested a delay in the development of
prion disease after inoculation with two antiprion antibodies:
ICSM18 and ICSM35 (White et al., 2003). A separate study on
cell-surface PrPc revealed that this protein acts as the cellular
receptor for amyloid A oligomer (Kessels et al., 2010), the
key element in the pathophysiological process of Alzheimer’s
disease. The pathogenic association of PrPc and the A
oligomer is the leading cause of synaptic dysfunction, as
observed in Alzheimer’s disease (Calella et al., 2010). Hence,
disruption of this toxic interaction, with the help of PrPc-
specific monoclonal antibodies, could be an appropriate
therapeutic approach that can be targeted against both prion
and Alzheimer’s diseases (Kessels et al., 2010; Freir et al.,
2011). However, the use of antiprion antibodies as a passive
immunization agent cannot be considered absolutely without
risk, as there are a few inconsistent observations regarding the
safety of these agents. Two antiprion monoclonal antibodies,
IgG D13 and IgG P, can cause extensive neuronal loss upon
in vivo administration in the mouse brain hippocampus
(Solforosi et al., 2004). Although the exact molecular
mechanism of antibody-mediated toxicity is not clear, cross-
linking of the antibody has been reported to be the factor
responsible for this toxicity. In another comparative analysis
recently performed by Klohn and coworkers, in vivo admin-
istration of several antiprion antibodies, IgG D13, IgG P, IgG
ICSM18 and IgG ICSM35, into the left hippocampus of mouse
brain indicated that these monoclonal antibodies are nontoxic
(Klöhn et al., 2012). Therefore, the current challenge for the
development of prion therapeutics is to find tight-binding
monoclonal antibodies that are also safe for in vivo adminis-
tration. Structural studies on antiprion antibodies bound to
PrPc molecules will provide essential insights in this regard by
deciphering the structural features that are responsible for
tighter association. However, until now, few attempts have
been made to crystallize antiprion monoclonal antibodies
bound to their cognate PrPc molecules. The crystal structures
of two Fab fragments of monoclonal antibodies bound to the
cognate C-terminal parts of prion proteins are available in the
PDB: the Fab fragment of a potentially therapeutic antibody
ICSM18 bound to human PrPc (residues 119–231; PDB entry
2w9e; Antonyuk et al., 2009) and the Fab fragment of antibody
VRQ14 bound to ovine PrPc (residues 114–234; PDB entry
1tpx; Eghiaian et al., 2004).
19 antiprion monoclonal antibodies, POM1–POM19, were
produced against recombinant mouse PrPc (moPrPc) using a
prion-knockout mouse strain; among these antibodies, several
recognize the conformationally structured C-terminal domain
of PrPc (Polymenidou et al., 2008). Here, we report structural
studies on an antibody fragment, POM1 Fab, in complex with
the C-terminal folded domain of human PrPc (huPrPc; resi-
dues 120–230). In addition to these structural data, thermo-
dynamic binding studies on POM1 Fab and huPrPc suggest a
moderately strong association between them. The antibody
fragment POM1 Fab recognizes a portion of the huPrPc
epitope helix 1. Interestingly, the purportedly therapeutic
antibody fragment ICSM18 Fab also recognizes the huPrPc
epitope helix 1, although the binding modes of these two
antibodies towards huPrPc are vastly different. Based on the
available structural data for different prion–antibody
complexes, the nature of the intermolecular interactions
between PrPcs and their cognate antibody partners are
compared. Structural analyses of prion–antibody complexes
will play a key role in the design of therapeutic products
against prion diseases.
2. Materials and methods
2.1. Production and purification of recombinant PrPc
The cDNA encoding the C-terminal part of human PrPc
(huPrPc; residues 120–230), mouse PrPc (moPrPc; residues 90–
231), bovine PrPc (boPrPc; residues 103–242) and sheep PrPc
(ovPrPc; residues 94–233) were cloned in a pET15b plasmid
and transformed in Escherichia coli BL21 (DE3) (Stratagene)
cells. These PrPc genes contain a His6 affinity tag fused at the
C-terminus and preceded by a thrombin cleavage site that
allows removal of the affinity tag after protein purification.
The cells were grown in rich medium containing 0.1 mg ml1
ampicillin at 310 K and the prion proteins were expressed
mainly in the form of inclusion bodies. The cells were pelleted
by centrifugation at 8000 rev min1 for 20 min, taken up in
50 mM Tris, 200 mM NaCl pH 8.0 and the homogeneous
solution was then sonicated (4  30 s with a 60 s interval at
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50% amplitude). The inclusion bodies were spun down at
27 000g for 30 min and the pellet was extensively washed with
2% sodium deoxycholate in 50 mM Tris, 200 mM NaCl pH 8.0
followed by four buffer washes without detergent. Subse-
quently, the inclusion bodies were incubated in a denaturing
buffer consisting of 6M guanidinium hydrochloride, 10 mM
Tris–HCl, 100 mM NaH2PO4, 5 mM imidazole pH 8.0 for 1 h
at room temperature with constant stirring. The extracted
denatured prion proteins were then loaded onto an Ni–NTA
agarose column (Qiagen) at a flow rate of 1 ml min1 after the
addition of 10 mM reduced glutathione. The prion proteins
were refolded on the column by gradient application of buffer
A (denaturing buffer) and buffer B (10 mM Tris–HCl, 100 mM
NaH2PO4, 5 mM imidazole pH 8.0) as described by Yin et al.
(2003). Finally, the prion proteins were eluted with 300 mM
imidazole in buffer B at pH 5.8, exchanged with distilled water
and concentrated using Amicon Ultra centrifugal filters
(3 kDa molecular-weight cutoff, Millipore). The His6 affinity
tag of the huPrPc was removed by digestion with thrombin at a
huPrPc:thrombin ratio of 1:0.02(w:w) in 50 mM Tris pH 8.0,
150 mM NaCl, 2 mM EDTA at 303 K in a water bath over-
night. The purity of these prion proteins was confirmed by
SDS–PAGE and their concentration was measured by the
Bradford method (Bradford, 1976) using bovine serum
albumin as a standard.
2.2. POM1 Fab fragment production
The IgG1 POM1 hybridoma was prepared according to
Polymenidou et al. (2008). After hybridoma cell culture, the
antibody-enriched and cell-free medium was loaded onto a
Protein G Sepharose column and the POM1 antibody was
eluted with 0.1 M glycine pH 2.8. For Fab production, the
POM1 IgG1 (1 mg ml1) was digested with papain at a
POM1:papain ratio of 1:0.02(w:w) in 50 mM Tris pH 8.0,
150 mM NaCl, 20 mM EDTA, 20 mM cysteine. The papain
enzyme was inactivated by the addition of 30 mM iodoaceta-
mide after 5 h incubation at 310 K in a water bath. The POM1
digest was then concentrated and buffer-exchanged with
Protein A IgG-binding buffer (Thermo Scientific) and loaded
onto a Protein A Sepharose column (Pierce). The Fc fragment
and undigested POM1 IgG1 remained bound to the Protein A
column, whereas the POM1 Fab fragments were collected
in the flowthrough. The Fab fractions were exchanged with
50 mM Tris, 150 mM NaCl pH 8.0, concentrated and finally
assessed for homogeneity by Coomassie Brilliant Blue staining
after separation by SDS–PAGE.
2.3. Purification and crystallization of POM1 Fab–huPrPc
POM1 Fab and huPrPc were mixed in an equimolar ratio in
order to form the protein complex; the resulting complex was
subsequently purified by Superdex G-75 (Amersham Bio-
sciences) size-exclusion chromatography in a buffer solution
consisting of 50 mM Tris pH 7.0, 100 mM NaCl, 1 mM NaN3.
For crystallization studies, the purified protein complex was
concentrated to a final concentration of 10 mg ml1. Screening
of crystallization conditions for the POM1 Fab–huPrPc
complex was carried out using several commercial screening
solutions from Hampton Research in 96-well Intelli-Plates
(Hampton Research) with the aid of a crystallization robot
(Hydra 96 Plus One, Robbins Scientific). Crystallization trays
were set up by the sitting-drop vapour-diffusion method, in
which 0.4 ml protein sample was mixed with an equal volume
of screening solution. An initial crystallization hit was found in
a saturating solution of 25% PEG 3350, 0.1 M MES pH 6.5,
0.1 M sodium acetate. After a few optimization steps similar to
those used to obtain diffraction-quality crystals of the POM1
Fab–moPrPc complex, POM1 Fab–huPrPc protein-complex
crystals were obtained within 7 d with approximate dimen-
sions of 0.6  0.2  0.3 mm (Baral et al., 2011).
2.4. Data collection and structure determination
The POM1 Fab–huPrPc complex crystals were picked up
directly from the sitting drop for data collection; 20% glycerol
was used as a cryoprotecting solution. Intensity data were
collected at the Canadian Light Source, Saskatoon,
Saskatchewan. Data were processed using the MOSFLM
program (Leslie, 2006). The data-collection details and the
refinement statistics are presented in Table 1. The protein-
complex structure was solved by the molecular-replacement
method using the program MOLREP (Vagin & Teplyakov,
2010) in the CCP4 package (Winn et al., 2011). An Fab
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Table 1
Summary of crystallographic data-collection and refinement statistics for
the POM1 Fab–huPrPc complex.
Values in parentheses are for the highest resolution shell.
Data-collection statistics
Space group C2
Resolution (Å) 76.5–2.4 (2.53–2.40)











Solvent content (%) 58
Refinement statistics













Bond lengths (Å) 0.017









i IiðhklÞ, where hI(hkl)i is the mean








hkl jFobsj for reflections in the working and test (5% of the data) sets.
structure from the PDB (PDB entry 2w9e; Antonyuk et al.,
2009) was used as the search model for the Fab molecule in the
POM1 Fab–huPrPc complex. The prion protein was then
searched for in the POM1 Fab–huPrPc complex using the
coordinates of human prion protein (PDB entry 3hak; Lee et
al., 2010) as the search model. Models were refined using the
refinement program of the PHENIX package (Afonine et al.,
2012). The progress of the refinement process was monitored
by reduction of both the R and Rfree factors. Solvent molecules
were added to the model in an automated manner in PHENIX
and water molecules were accepted only when well defined
positive peaks were present in both 2|Fo|  |Fc| and |Fo|  |Fc|
electron-density maps and there was a satisfactory hydrogen-
bonding network with either protein atoms or other water
molecules. Model building was performed with the program
Coot (Emsley & Cowtan, 2004). The coordinates and the
structure factors for the POM1 Fab–huPrPc complex have
been deposited in the PDB as entry 4dgi.
2.5. Isothermal titration calorimetry
A VP-ITC microcalorimeter (Microcal, Northampton,
Massachusetts, USA) was used to analyze the binding of
POM1 Fab and huPrPc. The proteins were dialyzed against
50 mM NaH2PO4 pH 6.0, 200 mM NaCl and degassed prior
to analysis. POM1 Fab was injected into the sample cell and
huPrPc (50 mM solutions) was placed into the syringe, or vice
versa with the exception that a slightly higher concentration of
POM1 Fab was used (60 mM). The dialysis buffer was placed
in the reference cell. Either POM1 Fab or huPrPc was titrated
against the dialysis buffer to obtain the heat of dilution. The
following parameters were used in the titration: 303 K, 10 ml
injections and 4 min between injections with stirring at
305 rev min1. The titration data were fitted using Origin v.5.0
(MicroCal) to extract the thermodynamic parameters.
2.6. ELISA
The antibody fragment POM1 Fab, generated by papain
digestion of POM1 IgG1 from the mouse hybridoma, was
immobilized on the solid surface of the wells of a 96-well plate
at a concentration of 0.01 mg ml1 and was incubated over-
night at 277 K. Unoccupied hydrophobic sites on the surfaces
of the plastic wells were blocked by the application of 3%(w/v)
BSA in PBS buffer pH 7.2 at room temperature for 2 h. Excess
reactants were washed away with PBS buffer containing
0.05% Tween-20, followed by several washes with PBS buffer
only. Recombinant polyhistidine-tagged fusion prion protein
analytes from mouse (moPrPc 90–231), bovine (boPrPc 103–
242) and sheep (ovPrPc 90–230) were added to the wells at
increasing dilutions in 3% BSA and PBS buffer and were
subsequently incubated for 2 h at room temperature with
gentle shaking. After washing as described previously, His-
Probe-HRP (Thermo Scientific) at a dilution of 1:5000 was
added and the plate was kept at room temperature for 1 h. For
colour detection, SureBlue Reserve TMB Microwell Perox-
idase Substrate (1-Component) was added after washing and
the reaction was stopped after 10 min by the addition of 1 M
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Figure 1
The crystal structure of the protein complex between the C-terminal domain of the recombinant human prion protein (120–230) and POM1 Fab. (a) The
human prion protein is shown in magenta; the heavy chain and the light chain of POM1 Fab are represented in orange and green, respectively. (b) A
close-up of the intermolecular contacts between POM1 Fab and the human prion protein. Hydrogen-bonding interactions are shown as dashed lines
(distances are given in Table 3).
HCl. Subsequently, the absorbance was measured at a wave-
length of 450 nm using a SpectraMax 190 microplate reader
(Molecular Devices Corporation).
3. Results
The intermolecular contacts between huPrPc and the POM1
Fab have been investigated by determining the crystal struc-
ture of the folded C-terminal domain of huPrPc (120–230) in
complex with the Fab fragment of POM1 at a resolution of
2.4 Å (Fig. 1a, Table 1 and Supplementary Table S11). The
overall fold of the C-terminal domain of huPrPc consists of
two short antiparallel -strands (residues 129–131 and 161–
163) and three -helices (residues 146–158, 174–196 and 203–
230). Electron density for the six N-terminal residues (residues
120–125) and the seven C-terminal residues (residues 223–
230) of huPrPc was not visible in the electron-density map. The
crystallographic data have a high average B factor because
certain regions of the protein complex, especially the constant
domains of both the POM1 Fab light chain and the POM1 Fab
heavy chain, are less well ordered. However, the binding
interface between huPrPc and the POM1 Fab is relatively well
ordered. The structural fold observed for huPrPc bound to the
POM1 Fab is similar to the available X-ray structures in the
PDB and to the various NMR structures of huPrPc proteins.
Structural superposition of the huPrPc protein bound to
POM1 Fab with huPrPc solved by X-ray crystallography (PDB
entry 3hak; Lee et al., 2010) and by NMR spectroscopy (PDB
entry 1qm1; Zahn et al., 2000) revealed overall root-mean-
square deviations (r.m.s.d.s) of 1.0 and 1.8 Å, respectively, for
the main-chain C atoms in the residue range 125–223 (Table 2
and Supplementary Fig. S11). However, striking differences
have been observed between this monomeric form of the
huPrPc protein structure bound to an antibody Fab fragment
and the crystal structure of a domain-swapped dimeric huPrPc
protein (PDB entry 1i4m; Knaus et al., 2001). In the dimeric
huPrPc conformation, helix 3 from one monomer is swapped
with helix 3 from the other monomer of the dimer by forming
two intermolecular disulfide bridges, unlike the single intra-
molecular disulfide bridge present between helix 3 and helix
2 of the huPrPc monomer (Knaus et al., 2001).
3.1. Structure of the POM1 Fab–huPrPc complex
The globular folded domain of huPrPc interacts with the
POM1 Fab mainly through the C-terminal part of the loop
joining strand 1 and helix 1 (residues 140–147). The
secondary binding epitope for the POM1 Fab involves three
noncontiguous residues, Lys204, Arg208 and Gln212, on helix
3 of huPrPc (Fig. 1b). This discontinuous prion epitope
observed for the POM1 Fab is partially in agreement with the
previous epitope-mapping experiment, which revealed helix
1 to be the primary epitope (Polymenidou et al., 2008).
Formation of the POM1 Fab–huPrPc complex buries a surface
area of 580 Å2, which is 9% of the total accessible surface
area of the ordered folded domain of huPrPc. The major
portion of this interaction interface is contributed by the
heavy chain of the POM1 Fab. Several residues from the three
complementarity-determining regions (CDRs) of the POM1
Fab heavy chain (CDR H1, residues 25–33; CDR H2, residues
52–56; CDR H3, residues 98–107) are in contact with the
huPrPc protein (Fig. 2a). Two neighbouring negatively charged
residues from CDR H2, Asp52 and Asp55, form salt-bridge
interactions with a positively charged residue, Arg208, of
huPrPc. These partially buried salt bridges, Arg208–Asp52 and
Arg208–Asp55, are present in the interface of POM1 Fab and
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Figure 2
Intermolecular contacts between the surface of human prion protein and POM1 Fab. (a) Human prion protein (grey) with POM1 Fab variable heavy
chain (magenta). (b) Human prion protein (grey) with POM1 Fab variable light chain (green).
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: RR5023). Services for accessing this material are described at the
back of the journal.
huPrPc; the latter salt bridge forms three hydrogen bonds
owing to excellent geometry between the oppositely charged
residues (Fig. 2a and Table 3). Although hydrophobicity is
viewed as the major force in protein–protein interactions,
electrostatic forces still make an important contribution
towards the association rate and this defines the lifetime of a
complex (Sinha & Smith-Gill, 2002). Additionally, the guani-
dium group of Arg208 also participates in a cation– inter-
action (Crowley & Golovin, 2005) with the aromatic ring of
Tyr57, which is also part of the CDR H2 region. The distance
between the plane of the guanidinium group and the aromatic
ring centre is 3.5 Å; this interaction between the CDR H2
paratope and the helix 3 epitope is strengthened by an
additional hydrogen bond between the hydroxyl group of
Tyr57 and the protonated N" atom of Lys204. Two aromatic
residues in the CDR H3 region, Tyr101 and Tyr104, make
research papers
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Figure 3
The structures of recombinant human and sheep prion proteins bound to antibody Fab fragments. The prion proteins are shown in green and the light
chain and the heavy chain of the bound Fab fragments are represented in magenta and cyan, respectively. The N-glycosylation sites on the prion proteins
are shown as spheres. (a) Human prion protein with POM1 Fab. (b) Human prion protein with ICSM18 Fab (Antonyuk et al., 2009). (c) Sheep prion
protein with VRQ14 Fab (Eghiaian et al., 2004).
Table 3
Summary of interactions between huPrPc and POM1 Fab in the crystal
structure.
huPrPc POM1 Fab Distance (Å)
POM1 Fab light chain
Gly142 O Tyr96 OH 2.3
Ser143 OH Asn92 O 3.4
Asp144 OD2 Ser32 OH 2.4
Asp144 OD2 Ser91 OH 3.3
Asp144 N Ser91 O 2.8
Asp 144 OD1 Tyr50 OH 2.6
Asp144 N Asn92 O 3.4
Tyr145 N Asn92 O 3.0
POM1 Fab heavy chain
His140 O Trp33 NE1 3.3
His140 NE2 Tyr101 OH 3.5
Gly142 N Tyr104 OH 3.3
Asp147 OD2 Tyr104 OH 2.9
Lys204 NZ Tyr57 OH 3.9
Arg208 NH1 Asp52 OD2 2.8
Arg208 NH1 Asp55 OD1 3.2
Arg208 NH1 Asp55 OD2 3.1
Arg208 NE Asp55 OD2 2.8
Gln212 NE2 Asp55 OD2 3.0
Table 2
Root-mean-square deviation (r.m.s.d.) in Å for backbone superimposi-
tion of PrPcs.
The main-chain atoms (residues 126–222) of the huPrPc X-ray structure (PDB
entry 3hak; Lee et al., 2010), the huPrPc NMR structure (PDB entry 1qm1;
Zahn et al., 2000), POM1 Fab–huPrPc (this work), ICSM18 Fab–huPrPc (PDB
entry 2w9e; Antonyuk et al., 2009) and VRQ14 Fab–ovPrPc (residues 129–225;
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hydrogen bonds to residues His140 and Asp147 of the huPrPc
protein. The abundance of aromatic and hydrophobic side
chains in antigen–antibody interaction interfaces and their
functional role during protein-complex formation has been
well established (Ramaraj et al., 2012).
Compared with the heavy chain, the light chain makes a
considerably smaller contribution towards the prion–antibody
interaction. Only a few residues of the POM1 Fab light chain
CDR L2 (residues 90–102) make contact with the N-terminal
part of helix 1: Ser91, Asn92 and Tyr96 (Fig. 2b). The main-
chain atoms of both interacting partners are involved in these
contacts; the carbonyl groups of Ser91 and Asn92 of the
POM1 Fab light chain CDR L2 region form hydrogen bonds
to the main-chain amide N atoms of huPrPc residues Asp144
and Tyr145, respectively. The positive end of the N-terminal
part of helix 1 seems to be stabilized through the backbone
carbonyl groups of the CDR L2. Additionally, the hydroxyl
groups of Tyr96 and Ser91 of the CDR L2 are also in contact
with the main-chain carbonyl group of Gly142 and the
carboxylate group of Asp144 of huPrPc. Two other residues,
Ser32 of the POM1 Fab light chain CDR L1 (residue range
25–33) and Tyr50, make contact with Asp144 of the huPrPc
protein (Fig. 2b and Table 3). In addition to several hydrogen-
bonding interactions between the interacting partners, two
tryptophan residues, one from the light chain and one from the
heavy chain, Trp94 and Trp33, provide a hydrophobic envir-
onment for protein-complex formation.
3.2. Structural comparisons among different antibody
Fab–PrPc complexes
Three different binding modes for the folded C-terminal
parts of the prion proteins are observed in the POM1 Fab–
huPrPc, ICSM18 Fab–huPrPc and VRQ14 Fab–ovPrPc protein
complexes (Fig. 3; for a sequence alignment of the variable
regions of these Fab fragments, see Supplementary Fig. S2).
Structural superpositions of the bound PrPc in the different
complexes indicate limited conformational variations among
them (Table 2). The purportedly therapeutic antibody frag-
ments ICSM18 Fab and POM1 Fab both recognize an epitope
on or near to helix 1 of huPrPc. The binding epitopes for
these two antibodies are non-overlapping but lie in close
proximity to one another. The Fab fragment of ICSM18
interacts with huPrPc only through helix 1, and the residues
of huPrPc involved in this interaction are in the range 142–153
(Antonyuk et al., 2009). Although both of the antibody Fab
fragments, POM1 Fab and ICSM18 Fab, recognize adjacent
huPrPc epitopes, the modes of binding of the prion molecules
to the respective cognate antibodies are completely different.
The common huPrPc epitope, helix 1, is bound to the Fab
fragments of these antibodies in an opposite manner. Upon
superimposing the Fab fragments of the POM1 and ICSM18
antibodies, the bound huPrPc molecules in the respective
CDRs are related to one another by an180 rotation (Fig. 4).
The Fab fragment of VRQ14 binds to ovPrPc in a comple-
tely different fashion and has a larger epitope that encom-
passes the N-terminal residues of helix 3 and the loop joining
helix 2 and helix 3. This antibody recognizes a prion epitope
that would be accessible in both PrPc and PrPsc (Eghiaian et
al., 2004). Previous structural studies on the VRQ14 Fab with
ovPrPc provides some crucial information on the secondary-
structural rearrangement during the pathological conversion
of PrPc to PrPsc (Eghiaian et al., 2004). Compared with the
interaction interface areas of the POM1 Fab–huPrPc complex,
larger buried surface areas are observed for the other two
prion–antibody complexes: surface areas of 863 and 987 Å2
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Figure 4
Structures of the POM1 Fab–huPrPc and ICSM18 Fab–huPrPc complexes are shown with identical orientations of the POM1 Fab and ICSM18 Fab
antibody fragments. (a) Structure of POM1 Fab bound to huPrPc. (b) Structure of ICSM18 Fab bound to huPrPc. HuPrPc is shown in green and the light
chain and the heavy chain of the bound Fab fragments are represented in magenta and cyan, respectively. An180 rotational shift of the bound huPrPc
is observed in the antibody–prion protein structures.
are buried in the ICSM18 Fab–huPrPc and VRQ14 Fab–
ovPrPc complexes, respectively. Unlike the POM1 Fab–huPrPc
complex, in which the POM1 Fab heavy chain is the major
interacting partner with huPrPc, the interaction interface is
evenly shared by the heavy chain and the light chain in the
ICSM18 Fab–huPrPc and VRQ14 Fab–ovPrPc complexes. The
nature of the interactions between the prion proteins and their
cognate antibodies are quite variable among these prion–
antibody complexes (Fig. 5). The molecular contacts between
huPrPc and ICSM18 are mostly electrostatic in nature. Three
negatively charged patches are observed on the electrostatic
surface map of ICSM18: one patch stabilizes the N-terminus of
helix 3, the second patch stabilizes the N-terminus of helix 1
and the third patch is involved with Arg148 of helix 1. Three
separately placed negatively charged residues on the ICSM18
Fab paratope form these charged centres: Asp31 and Asp35
from the ICSM18 Fab heavy chain and Asp49 from the
ICSM18 Fab light chain contribute to the electrostatic stabi-
lization of huPrPc. The contact surface between huPrPc and
the POM1 Fab is partially electrostatic in nature; a broad
negatively charged surface is present on the binding interface
of the POM1 Fab and stabilizes the positive electrostatic
potential mainly contributed by two residues, Arg208 and
His140, of huPrPc. A cluster of negatively charged residues
on the POM1 Fab paratope, Asp52, Asp55, Asp73 and Glu74,
contributes to this large patch of negatively charged surface.
Unlike the polar interface area for ICSM18 and POM1, a
broad hydrophobic interaction interface is observed for
VRQ14. This paratope of the VRQ14 Fab forms a groove-like
structure into which the ovPrPc molecule fits owing to shape
complementarity. Amongst the three prion–antibody
complexes, the POM1 Fab–huPrPc complex was found to be
most stable based on the results of shape-complementary
evaluation (Supplementary Table S2).
In the prion–antibody complexes, the flexibility of the
bound PrPc molecules is reduced significantly upon binding
to their cognate antibody Fab fragments. Upon POM1 Fab
binding, the regions of the huPrPc protein that make contact
with the POM1 Fab show reduced mobility compared with
the rest of the structure; a reduction in temperature factor is
research papers
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Figure 6
A representation of the thermal parameter distribution in prion proteins shown as B-factor ‘putty’ as implemented in PyMOL (http://www.pymol.org).
The C-atom B factors are depicted on the structure in dark blue (lowest B factor) through to red (highest B factor), with the radius of the ribbon
increasing from low to high B factor. (a) Human prion protein from the POM1 Fab–huPrPc complex. (b) Human prion protein from the ICSM18 Fab–
huPrPc complex. (c) Sheep prion protein from the VRQ14 Fab–ovPrPc complex.
Figure 5
Surface representations of the Fab fragments based on the electrostatic potential of the residues constituting them. The electrostatic potential was
calculated using the program DelPhi (Honig & Nicholls, 1995) with full charges assigned to Asp, Glu, Lys and Arg residues and partial charges assigned
to the backbone atoms. The colour range extends from 7kT/e (red) to +7kT/e (blue). (a) Human prion protein bound to POM1 Fab. (b) Human prion
protein bound to Fab ICSM18. (c) Sheep prion protein bound to VRQ14 Fab.
observed for these regions of huPrPc (Fig. 6a). During the
prion-misfolding process, helix 1 is considered to be the site
that is primarily responsible for initiating the transformation
of helical PrPc into -sheet-rich PrPsc. This observation has
been supported by several mutational analyses as well as by in
vitro studies on helix 1 (Eghiaian et al., 2004; Govaerts et al.,
2004). The binding of POM1 provides a stabilizing effect on
helix 1 that should inhibit any structural changes in the prion
protein. A lower temperature factor for this region of huPrPc
is observed because of POM1 Fab binding as well as ICSM18
Fab binding (Figs. 6a and 6b). The regions of huPrPc protein
that show a higher temperature factor in the ICSM18 Fab–
huPrPc complex are the C-terminal part of helix 2, the
N-terminus of helix 3 and the loop joining helix 2 and helix
3. Unlike the N-terminus of helix 3 of the huPrPc in the
ICSM18 Fab–huPrPc complex, this segment of huPrPc makes
contact with the POM1 Fab in the POM1 Fab–huPrPc
complex; therefore, a lower temperature factor is observed for
this region. In the VRQ14 Fab–ovPrPc complex a higher
temperature factor is observed for helix 1 of ovPrPc. This
region of ovPrPc remains on the opposite face to the part of
ovPrPc that makes contact with the VRQ14 Fab paratope in
the VRQ14 Fab–ovPrPc complex (Fig. 6c).
3.3. Binding studies of POM1 Fab with PrPc
We have used isothermal titration calorimetry (ITC) to
investigate the binding of the POM1 Fab antibody fragment
to the C-terminal structured domain of huPrPc. Titration of
POM1 Fab into solution containing huPrPc is shown in Fig. 7.
The POM1 Fab binds to huPrPc in a 1:1 ratio, with a disso-
ciation constant of 4.5  107 M. The titration plot was
derived from the integrated raw data and the solid line
represents the best least-squares fit to these data. The
variable parameters are best fitted using the following
values: n = 1.079  0.03, H = 12.0 kJ mol1 and
TS =31.61 kJ mol1. This binding event is an enthalpically
driven process, as shown in Fig. 7. Although the antibody
POM1 was specifically generated against recombinant
moPrPc, ELISA data indicate that the Fab fragment of this
antibody recognizes PrPcs from several different species,
especially boPrPc and ovPrPc, which share a high sequence
identity to moPrPc as well as to huPrPc (Supplementary Fig. S2
and Fig. S3). These data further suggest that the binding of the
POM1 Fab to PrPcs from other species are equally as strong as
the binding of the POM1 Fab to huPrPc.
4. Discussion
4.1. Structural analysis of the POM1 Fab–huPrPc complex
The binding of the antiprion antibody POM1 relies on the
tertiary structural fold of PrPc, as previous ELISA studies on
PrPc peptide fragments spanning the binding epitope failed to
show any binding (Polymenidou et al., 2008). The POM1 Fab–
huPrPc structural data clearly demonstrate that a particular
spatial arrangement of the discontinuous PrPc epitope is
essential in order to make contact with the POM1 paratope.
The Fab fragment of the POM1 antibody can potentially
recognize PrPc from different species, especially those of
boPrPc and ovPrPc, as observed from the ELISA data
(Supplementary Fig. S4). The high sequence identity among
the PrPcs from several mammalian species, particularly in
the POM1 epitope region, clearly explains the cross-species
reactivity of this antibody. Interestingly, several antiprion
monoclonal antibodies show varied affinity towards the
pathogenic PrPsc form along with their intrinsic binding
properties towards the native PrPc form. The VRQ14 antibody
has previously been shown to recognize PrPsc (Eghiaian et al.,
2004). Similarly, ICSM18 and POM1 can both recognize PrPsc
from scrapie-infected mouse brain homogenate, as demon-
strated in previously reported immunoprecipitation experi-
ments (Antonyuk et al., 2009; Polymenidou et al., 2008). This
promiscuous nature of certain antibodies indicated either a
certain degree of structural plasticity on the antigenic surfaces
of PrPc and PrPsc or the structural conservation of the PrPc
molecules within the PrPsc molecule, which is very unlikely.
Although the misfolding pathway that leads to PrPsc
formation is poorly understood, the existence of an aggrega-
tion-prone partially misfolded prion isoform, PrP, and its
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Figure 7
Isothermal titration calorimetry (ITC) measurements. Top, raw data from
ITC experiments performed at 298 K. Bottom, integrated heat changes
and the fitted curve based on a single-site model. 1 cal = 4.186 J.
involvement in PrPsc seed generation has been the most widely
accepted hypothesis to date (Govaerts et al., 2004; Silveira et
al., 2005). In this context, it will be interesting to learn exactly
what the initial oligomerization event of the PrP molecules is
that subsequently leads to PrPc misfolding and aggregration.
The intermolecular contacts that occur between neighbouring
PrPc molecules in a protein crystal through crystallographic
symmetry-related arrangements could provide valuable
information regarding this crucial oligomerization event. PrPc
molecules from several different species crystallized in a
variety of different space groups and under different crystal-
lization conditions have been observed to associate with each
other through their antiparallel -strands (Supplementary
Fig. S5a). This four-stranded -strand structure acquires
elements of a steric zipper in which residues from two
neighbouring -strands are tightly interdigitated. This
extended arrangement of -strands functions as a nidus, or
scaffold, for amyloid fibrils as well as for PrPsc and this early
phenomenon in scrapie generation has been extensively
studied by Eisenberg and coworkers (Nelson et al., 2005;
Sawaya et al., 2007). In the crystallographic symmetry-related
arrangement of the ICSM18–huPrPc protein complex, the
huPrPc molecules from neighbouring protein complexes are
also arranged in a similar way (Antonyuk et al., 2009). This
structural result on the steric zipper association of huPrPc
alone is not sufficient to explain the toxic aggregation process.
This phenomenon has only been observed in short peptides;
larger structural rearrangements are essential in the cases of
larger proteins that unfold completely. However, this unique
manner of PrPc association may have some biological rele-
vance. A different manner of oligomeric association has been
observed for huPrPc in the crystallographic symmetry-related
arrangement of the POM1 Fab–huPrPc complex (Supple-
mentary Fig. S5b). The adjacent huPrPc molecules interact
with one another through residues 136–138, which belong to
the loop structure joining helix 1 and strand 1. This obser-
vation excludes the possibility of stacking around the -strand
region of huPrPc upon binding to POM1.
4.2. PrPc binding and PrPsc inhibition
Several small-molecule chemical compounds that bind
tightly to the structured region of PrPc, behave like chemical
chaperones and inhibit PrPsc formation have been described
(Kuwata et al., 2007; Hosokawa-Muto et al., 2009). A recent
investigation of a cationic tetrapyrrole [Fe(III)-TMPyP]
compound that has been shown to reduce the levels of PrPsc in
scrapie-infected cells showed that it forms a 1:1 complex with
the structured C-terminal part of huPrPc; the dissociation
constant measured for this interaction was 4.5  2 mM (Nicoll
et al., 2010). Monoclonal antibodies have also been shown to
have PrPsc-reducing properties in the cellular model of prion
propagation as well as in in vivo animal models (White et al.,
2003; Féraudet et al., 2005). A correlation has been observed
between the binding affinity of the antibody towards PrPc and
its potential for inhibiting PrPsc propagation (Antonyuk et al.,
2009). In a comparative analysis of ICSM antibodies, their
effectiveness towards PrPsc reduction versus their binding
potential towards PrPc showed that the -PrP-binding ICSM
antibodies exhibited greater PrPsc reduction compared with
the -PrP-binding ICSM antibodies because of their higher
affinity for PrPc (Antonyuk et al., 2009). The Kd values for
these ICSM series of monoclonal antibodies remained in the
high-nanomolar to low-submicromolar range; these values
were estimated by ELISA using recombinant PrPc. The
Kd value for POM1 Fab–huPrP
c complex formation is
4.5  107 M and this medium-range binding affinity lies
between the binding affinities estimated for the -PrP-
recognizing and the -PrP-recognizing ICSM antibodies.
4.3. Structural implications of the antibody Fab–PrPc
complexes
In the three prion–antibody complexes analyzed in this
study, the PrPc epitopes recognized by these antibodies are
quite distinct and non-overlapping. The paratopes for these
different PrPc epitopes are also comprised of unrelated
structural features. Moreover, the molecular interactions
observed for these prion–antibody associations are quite
dissimilar in nature; electrostatic interactions predominate in
the binding of ICSM18 and POM1 to their respective huPrPc
molecules, while the interactions observed for VRQ14 with
ovPrPc are primarily hydrophobic in nature, although several
hydrogen bonds are present between the interacting partners.
Despite these marked differences, formation of stable prion–
antibody complexes is observed upon antibody binding. In
addition to the tight binding properties, in vivo accessibility
of the PrPc motif to these antiprion antibodies is another
important aspect that must be considered carefully in
designing potential therapeutic products. The presence of two
glycosylation sites, residues Asn181 and Asn197 of huPrPc, as
well as the C-terminal GPI anchor, might conceivably hinder
the accessibility of an antiprion antibody to its PrPc epitope in
a natively folded conformation. The recombinant PrPcs used
in the structural studies of these three prion–antibody
complexes are devoid of glycosylation. Although glycosylated
native PrPc and PrPcs from recombinant sources both possess
identical structural folds (Hornemann et al., 2004), the spatial
orientation of the glycan chain could limit the prion–antibody
association in vivo. Hence, structural information regarding
the two glycosylation sites of PrPc in reference to the binding
epitope of an antibody is extremely important in predicting
the biological role of this antibody. Antibody ICSM18 recog-
nizes the huPrPc epitope helix 1; however, one of the
glycosylation sites on huPrPc, Asn197, comes into close
proximity of the paratope of this antibody (Fig. 3b). Although
POM1 binds to the same helix 1 epitipe, its binding epitope is
mainly the N-terminus of helix 1 and the loop preceding helix
1. Therefore, a different mode of binding of the POM1 Fab
to huPrPc results in the globular domain of the huPrPc being
rotated by 180 relative to its orientation in the antigen-
combining site of ICSM18 Fab (Fig. 4). This different orien-
tation of huPrPc in the POM1 Fab results in both glycosylation
sites of huPrPc facing away from the POM1 Fab and into the
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surrounding solution (Figs. 3a and 3b). Thus, there is no steric
interference from either of the covalently attached carbo-
hydrate residues on huPrPc with the POM1 Fab or the POM1
monoclonal antibody. Like ICSM18, the epitope recognized
by VRQ14 is immediately adjacent to Asn200, which is one of
the two sites of glycosylation on ovPrPc (Fig. 3c).
These structural results for the protein complexes analyzed
in this study have several important implications. Firstly, the
bound conformation observed in the crystals of POM1 Fab–
huPrPc will be the same as those that would be adopted by
the POM1 Fab or the POM1 IgG1 when bound in vivo. This
observation is well supported by an in vivo experimental study
on mouse brain slices, which indicated that POM1 IgG1 can
readily recognize prion proteins in a physiologically relevant
system (Polymenidou et al., 2008). Secondly, the Kd that has
been measured for the binding of POM1 Fab to huPrPc should
also be the same for the in vivo situation. On the other hand,
the binding of ICSM18 Fab or its IgG and of VRQ14 Fab or its
IgG will have at least two different conformations in vivo and
will quite likely have two different corresponding Kd values.
The conformation of ICSM18 Fab bound to huPrPc will only
be the same in vivo as that observed in the crystal structure for
the unglycosylated form of huPrPc and the monoglycosylated
form (Asn181) of huPrPc. The monoglycosylated huPrPc
(Asn197) and the diglycosylated huPrPc will both present a
strong steric clash with either the ICSM18 Fab or the ICSM18
IgG so that the binding mode is certain to be perturbed and
different from that observed in the crystal structure. The loop
structures on the ICSM18 Fab paratope could adopt confor-
mations that would possibly relieve the steric clash that would
result from the presence of carbohydrate residues on Asn197.
This altered in vivo binding of ICSM18 Fab to huPrPc would
certainly be associated with an altered value of Kd and very
likely a less avid interaction than that measured for the
recombinant huPrPc. Similarly, a less avid interaction resulting
from a perturbed binding mode can be predicted for in vivo
association of the VRQ14 Fab or its IgG with native ovPrPc.
5. Conclusions
The crystal structure of the POM1 Fab–huPrPc complex was
determined at 2.4 Å resolution. It demonstrates that the
POM1 Fab binds to the structured domain of huPrPc through a
discontinuous epitope comprised of a loop between strand 1
and helix 1, the N-terminus of helix 1 and three residues
from helix 3. This POM1 epitope is also in close vicinity to
the epitope recognized by the purportedly therapeutic anti-
body ICSM18. The measured Kd value for the association of
POM1 Fab and huPrPc remains midway between theKd values
observed for the ICSM series of therapeutic antibodies.
Therefore, a similar functional role can be predicted for
POM1. Structural analysis of the three prion–antibody
complexes presented here is a step forward towards under-
standing the interplay of hydrogen bonding and other mole-
cular interactions between prion proteins and their cognate
monoclonal antibodies. There is a diverse nature of molecular
interactions that are responsible for association between the
paratopes and the epitopes. This knowledge will further
facilitate the design of better prion-protein binders through an
antibody-engineering approach. Although the structural data
presented here are based on prion proteins from recombinant
sources, many meaningful conclusions can be derived on the
in vivo associations of glycosylated prion proteins and these
antibodies. However, detailed structural studies are needed on
the glycosylated native forms of the prion proteins along with
their cognate antiprion antibodies in order to better illustrate
the proposed mechanism of in vivo accessibility and binding.
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Féraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Créminon,
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